Achillion Announces Termination of Worldwide Collaboration for Hepatitis C With Janssen
September 11, 2017 03:01 ET
|
Achillion Pharmaceuticals, Inc.
-Conference call to be held today at 9:00 a.m. ET- NEW HAVEN, Conn., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that on Saturday, September 9,...
Achillion to Present at the 2017 JMP Securities Life Sciences Conference
June 15, 2017 16:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., June 15, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs
May 04, 2017 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., May 04, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three months ended March 31, 2017. For the first quarter of...
Achillion to Present at the Deutsche Bank 42nd Annual Health Care Conference
May 02, 2017 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., May 02, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178
April 22, 2017 03:00 ET
|
Achillion Pharmaceuticals, Inc.
AMSTERDAM, the Netherlands, April 22, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today the presentation of updated results from the ongoing phase 2 ‘604 Study’...
Achillion Reports 2016 Fourth Quarter and Year-End Financial Results
February 23, 2017 16:05 ET
|
Achillion Pharmaceuticals, Inc.
Complement factor D inhibitor program on track for initiation of ACH-4471 phase II trial for treatment-naïve PNH patients during the first half of 2017Expanding complement platform includes internally...
Achillion Announces Clinical Milestone for the Advancement of JNJ-4178 in Phase 2B Development for Chronic HCV
December 28, 2016 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Dec. 28, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it has received a $15 million milestone payment from Janssen Research...
Achillion Announces Initiation of Patient Dosing by Janssen in a Global, Short Treatment-Duration Phase 2b Study of JNJ-4178 in Chronic HCV
November 30, 2016 06:05 ET
|
Achillion Pharmaceuticals, Inc.
- Janssen initiates dosing of patients in OMEGA-1: Phase 2b study evaluating six- and eight-week treatment durations with JNJ-4178, a 3DAA combination of odalasvir, simeprevir, and AL-335, for the...
Achillion Reports Third Quarter 2016 Financial Results And Provides Update On Clinical Programs
November 03, 2016 09:00 ET
|
Achillion Pharmaceuticals, Inc.
Janssen HCV triple combination candidate JNJ-4178 reported 100% SVR12 after 6 weeks of therapy; global phase IIB study to begin 4Q 2016Achillion’s phase I MAD study with oral factor D inhibitor...
Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen’s Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV
September 23, 2016 11:50 ET
|
Achillion Pharmaceuticals, Inc.
- ePoster presented today at the EASL / AASLD Special Conference: New Perspectives in Hepatitis C Virus Infection – The Roadmap For Cure - - Ongoing Phase 2 development focusing on triple...